Advanced oral drug delivery system for biologics and peptides
While pharmaceutical proteins and peptides such as those in the BCS Class III often have excellent solubility, their relatively poor levels of permeability can result in bioavailability challenges. Due to this poor bioavailability, as well as other issues including stability and a short plasma half-life, proteins and peptides have traditionally been developed for parenteral administration.
With the development of EUDRATEC® PEP, Evonik has created a modular platform technology to improve the oral bioavailability of peptides and proteins, as well as small and medium sized biopharmaceuticals. Designed for use in multiparticulates or mini-pellet dosage forms, the oral drug delivery system creates attractive opportunities to improve patient compliance, reduce manufacturing costs and improve product differentiation. A variety of synergistic modules with different functionalities, including gastrointestinal targeting, enzymatic protection and absorption, can be efficiently combined in each microparticle, to overcome specific physiological challenges and ensure proper bioavailability.
